HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacia & Upjohn Rogaine 5% new clinical trials in women to begin shortly.

This article was originally published in The Rose Sheet

Executive Summary

P&U PURSUING SEPARATE APPROVAL OF ROGAINE EXTRA STRENGTH FOR WOMEN with data from additional clinical trials that are slated to begin shortly, the company said at a July 16 joint meeting of FDA's Nonprescription Drugs and Dermatologic & Ophthalmic Drugs Advisory Committees in Bethesda, Md. Pharmacia & Upjohn first attempted to gain approval for use of 5% minoxidil solution in both men and women but results from the initial round of clinical trials did not show statistically significant efficacy in women. The committees voted to recommend approval for Rogaine Extra Strength for use by men for the indication "more hair regrowth" ("The Rose Sheet" July 21, p. 5).
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS004451

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel